Please assess the completion status of the following clinical trial:

Trial Title: A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologically confirmed metastatic adenocarcinoma of the pancreas (AJCC Stage IV). Subjects with islet cell neoplasms are excluded~* Non-measurable or measurable disease based on the RECIST criteria~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1~* Life expectancy of \> 3 months~* Hematologic function, as follows:~  * Absolute neutrophil count (ANC) ≥ 1.5 x 109/L~ * Platelet count ≥ 100 x 109/L~ * Hemoglobin ≥ 9 g/dL (transfusion independent)~* Renal function, as follows:~  * Creatinine ≤ 2.0 mg/dL~* Hepatic function, as follows:~  * Aspartate aminotransferase (AST) ≤ 2.5 x ULN or ≤ 5 x ULN if known liver metastases.~ * Alanine aminotransferase (ALT) ≤ 2.5 x ULN or ≤ 5 x ULN if known liver metastases~ * Bilirubin ≤ 2 x ULN~* INR \< 1.3 (or ≤ 3 if on warfarin for therapeutic anti-coagulation)~Exclusion Criteria:~* Prior systemic therapy for metastatic pancreatic cancer~  * Subjects who have received adjuvant treatment with gemcitabine and who had relapse metastatically are allowed~ * Subjects with advanced local disease who have received treatment with gemcitabine and in whom progression has been observed with the onset of metastases less than 6 months are excluded~* Chemotherapy and/or radiation within 4 weeks of study enrollment~* Prior monoclonal antibody therapy within 60 days of study enrollment~* Known brain or leptomeningeal disease~* History of other primary malignancy, unless:~  * Curatively resected non-melanomatous skin cancer~ * Other malignancy curatively treated with no known active disease present and no treatment administered for the last 3 years~* Active angina or Class III or IV Congestive Heart Failure (New York Heart Association CHF Functional Classification System)~* Use of any investigational product within 4 weeks of study enrollment~* Major surgery (that requires general anesthesia) within 4 weeks before study enrollment~* Women who are pregnant (confirmed by positive pregnancy test) or lactating~* Man or woman of childbearing potential not consenting to use adequate contraceptive precautions during the course of the study and for 4 weeks after the last AGS-1C4D4 and/or gemcitabine infusion administration~* Subject known to be human immunodeficiency, hepatitis B or hepatitis C virus positive~* Active serious infection not controlled with antibiotics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1. Gemcitabine monotherapy (Type: ACTIVE_COMPARATOR): None
- 2. Gemcitabine plus AGS-1C4D4 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).